Medical Equipment & Devices

FNArena Windows (Sectors)

Introduction to FNArena Windows

FNArena Windows offers subscribers the option to investigate ASX-listed stocks against their peers. FNArena developed its own sector methodology which in our view overcomes many flaws and disadvantages connected with GICS sectors. Our system starts with three broad sector labels: COMMODITIES, FINANCIAL SERVICES and INDUSTRIALS. From here onwards subscribers can explore further through gradually narrowing branches. This is not investment advice, but simply another window on the Australian Stock Exchange to provide better insight and to assist FNArena subscribers while conducting their own market analysis.

Latest Stories
CAT Gable Feb 2025

Michael Gable of Fairmont Equities sees an ongoing uptrend for shares in Catapult Group International

Feb 18 2025

Good Governance

Addressing challenges and opportunities in meeting the UN Sustainable Development Goals and what ESG characteristics underpin share prices

Feb 07 2025


ASX CODE COMPANY NAME LAST PRICE 52WK HIGH 52WK LOW P/E CONSENSUS TARGET
4DX 4DMEDICAL LIMITED $0.55 $0.83 $0.41

$0.85

CAT CATAPULT GROUP INTERNATIONAL LIMITED $3.82 $4.08 $1.20

$4.00

COH COCHLEAR LIMITED $271.92 $350.31 $261.38 46.6

$285.54

CU6 COCHLEAR LIMITED $3.43 $8.98 $2.50

$10.00

CVB CURVEBEAM AI LIMITED $0.14 $0.29 $0.09

$0.26

CYC CYCLOPHARM LIMITED $1.93 $xx.xx $xx.xx xx.x xx.xx
EBR EBR SYSTEMS INC $1.64 $xx.xx $xx.xx xx.x xx.xx
FPH FISHER & PAYKEL HEALTHCARE CORPORATION LIMITED $31.65 $xx.xx $xx.xx xx.x xx.xx
IDX INTEGRAL DIAGNOSTICS LIMITED $2.95 $xx.xx $xx.xx xx.x xx.xx
IME IMEXHS LIMITED $0.40 $xx.xx $xx.xx xx.x xx.xx
IMR IMRICOR MEDICAL SYSTEMS INC $1.52 $xx.xx $xx.xx xx.x xx.xx
IPD IMPEDIMED LIMITED $0.05 $xx.xx $xx.xx xx.x xx.xx
MX1 MICRO-X LIMITED $0.07 $xx.xx $xx.xx xx.x xx.xx
NAN NANOSONICS LIMITED $4.26 $xx.xx $xx.xx xx.x xx.xx
ONE ONEVIEW HEALTHCARE PLC $0.33 $xx.xx $xx.xx xx.x xx.xx
PGC PARAGON CARE LIMITED $0.54 $xx.xx $xx.xx xx.x xx.xx
PME PRO MEDICUS LIMITED $286.09 $xx.xx $xx.xx xx.x xx.xx
RMD RESMED INC $36.77 $xx.xx $xx.xx xx.x xx.xx
TRJ RESMED INC $0.81 $xx.xx $xx.xx xx.x xx.xx
Previous Stories
ResMed Shakes Off GLP-1 Scare

Feb 04 2025

The great obesity drug scare of 2023 is now behind ResMed as evidence in the December quarter suggests GLP-1s are actually a positive for the sleep apnoea industry


ResMed: Another Positive Quarterly Surprise?

Jan 30 2025

Tomorrow’s release is expected to reveal another strong quarter from ResMed


The Trend Remains Pro Medicus’ Friend

Jan 16 2025

The Chartist reports shares in Pro Medicus are having a breather, with the uptrend likely to continue


Diagnostic Imaging Radiates Opportunity

Dec 18 2024

Pending MRI deregulation is behind the now approved merger of Integral Diagnostics and Capitol Health, and analysts see significant opportunity


ResMed’s Bounce-Back Complete

Oct 29 2024

A stellar first quarter has underscored ResMed’s share price bounce-back from last year’s obesity drug panic, and perhaps put to bed the initial fear of GLP-1s


Dr Boreham’s Crucible: Pro Medicus

Sep 04 2024

The New Criterion’s Tim Boreham explains the ins and outs of one of the undisputed star performers on the ASX


Pro Medicus: Don’t Stop Me Now

Aug 20 2024

Michael Gable of Fairmont Equities reports it doesn’t look like Pro Medicus shares are in a mood to stop rising any time soon


Dr Boreham’s Crucible: Blinklab

May 20 2024

Recently ASX-listed Blinklab claims the world’s best mobile phone app for detecting autism, the New Criterion’s Tim Boreham reports


ResMed Silences The Doubters

Apr 29 2024

A forecast-beating jump in gross margins was the highlight in ResMed’s March quarter result


Dr Boreham’s Crucible: 4D Medical

Apr 23 2024

The New Criterion’s Tim Boreham uncovers the potential of 4D Medical in the USA